Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis. 1990

D Debruyne, and J P Ryckelynck, and M Moulin, and B Hurault de Ligny, and B Levaltier, and M C Bigot
Pharmacology Laboratory, University Hospital Centre of Caen, France.

The pharmacokinetics of fluconazole given orally (100 mg) or intraperitoneally (50 and 150 mg) were determined in 15 patients with chronic renal failure who were undergoing continuous ambulatory peritoneal dialysis. The half-life (72 to 85 hours) was intermediate between values obtained in healthy volunteers and in patients with renal insufficiency studied during an interhaemodialysis period. The peritoneal clearance, 0.26 to 0.33 L/h, led to an 18% recovery of administered drug in the dialysates after 48 hours. The peritoneal absorption was slow (time to peak plasma concentration 7 hours) but the peritoneal bioavailability was excellent at 87 +/- 5%. The mean concentrations of fluconazole up to 24 hours were 770 and 1900 micrograms/L after single intraperitoneal doses of 50 and 150 mg, respectively. The volume of distribution (40 to 60 L) did not differ from that determined in patients with normal renal function. In the case of fungal peritonitis essentially attributed to Candida spp., a 6-hour intraperitoneal infusion of fluconazole 150 mg every 2 days appears to be a good regimen to rapidly exceed minimum inhibitory concentrations and treat infection without risk of systemic dissemination of fungi or toxicity.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

D Debruyne, and J P Ryckelynck, and M Moulin, and B Hurault de Ligny, and B Levaltier, and M C Bigot
July 1992, Antimicrobial agents and chemotherapy,
D Debruyne, and J P Ryckelynck, and M Moulin, and B Hurault de Ligny, and B Levaltier, and M C Bigot
January 2003, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
D Debruyne, and J P Ryckelynck, and M Moulin, and B Hurault de Ligny, and B Levaltier, and M C Bigot
April 1981, Antimicrobial agents and chemotherapy,
D Debruyne, and J P Ryckelynck, and M Moulin, and B Hurault de Ligny, and B Levaltier, and M C Bigot
April 1988, The Japanese journal of antibiotics,
D Debruyne, and J P Ryckelynck, and M Moulin, and B Hurault de Ligny, and B Levaltier, and M C Bigot
May 1984, Antimicrobial agents and chemotherapy,
D Debruyne, and J P Ryckelynck, and M Moulin, and B Hurault de Ligny, and B Levaltier, and M C Bigot
March 1984, Antimicrobial agents and chemotherapy,
D Debruyne, and J P Ryckelynck, and M Moulin, and B Hurault de Ligny, and B Levaltier, and M C Bigot
August 1983, Antimicrobial agents and chemotherapy,
D Debruyne, and J P Ryckelynck, and M Moulin, and B Hurault de Ligny, and B Levaltier, and M C Bigot
January 2009, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis,
D Debruyne, and J P Ryckelynck, and M Moulin, and B Hurault de Ligny, and B Levaltier, and M C Bigot
May 1988, Journal of clinical pharmacology,
D Debruyne, and J P Ryckelynck, and M Moulin, and B Hurault de Ligny, and B Levaltier, and M C Bigot
January 1986, Nephron,
Copied contents to your clipboard!